Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vidutolimod + cemiplimab
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intravenous, Subcutaneous
01
Overview
Vidutolimod + cemiplimab is a combination investigational cancer immunotherapy regimen. **Vidutolimod** (CMP-001) is a virus-like particle biologic functioning as a Toll-like receptor 9 (TLR9) agonist, delivered intratumorally to stimulate innate and adaptive immune responses and enhance anti-tumor activity. **Cemiplimab** (REGN2810, brand name Libtayo) is a monoclonal antibody directed at programmed cell death protein 1 (PD-1), blocking this checkpoint to restore T-cell anti-tumor activity. This combination is being tested for its ability to enhance immune responses in patients with various advanced or metastatic cancers, including refractory cases.
- Other names
- vidutolimodcemiplimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on vidutolimod + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vidutolimod + cemiplimab.